Anti-SARS-CoV-2 IgM positivity raised from 10 to 16.6% in CVID patients, HC control positivity rise was also limited from 6.6% to 20%; Anti-SARS-CoV-2 NP IgG was negative in both groups at both time points correlating with no prior COVID-19 clinical infection. This evidence concerns the gene CD40LG and common variable immunodeficiency.